Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc. operates as a biopharmaceutical company, which provides disease-modifying solutions for neurodegenerative diseases. The firm focuses on streamlined clinical development and drug discovery. It specializes in developing a proprietary therapeutic for Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases that target the neuroinflammation and nerve cell death that characterize these disorders. The company was founded by Joshua Cohen and Justin Klee in 2013 and is headquartered in Cambridge, MA.

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Amylyx Pharmaceuticals excels in Q4 with RELYVRIO launch success

Amylyx Pharmaceuticals demonstrated strong financial performance in Q4 2022, driven by the successful commercial launch of RELYVRIO for ALS treatment.
The company's focus on key priorities for the U.S. launch and commitment to serving ALS patients position it well for future growth and impact.
While facing challenges in meeting analyst expectations and study success criteria, Amylyx Pharmaceuticals remains optimistic about the opportunities ahead in advancing ALS treatment.

Amylyx Pharmaceuticals achieves profitability in Q1, plans global PSP study

Amylyx Pharmaceuticals delivered strong financial performance in Q1, driven by the success of RELYVRIO and plans for AMX0035 in PSP. While facing challenges in profitability expectations and pipeline expansion, the company is well-positioned to capitalize on opportunities for growth and impact.

Amylyx Pharmaceuticals reports robust Q2 performance and strategic growth focus

Amylyx Pharmaceuticals' Q2 2023 Earnings Call highlighted strong financials, patient-centric initiatives, and advancements in R&D programs for neurodegenerative diseases.
Analysts' inquiries underscored the need for clarity on compliance rates, expansion strategies, and study design considerations to address potential challenges.
The company's emphasis on trial design strength, patient support, and market positioning opportunities signals a strategic focus on growth and innovation.

Amylyx Pharmaceuticals reports strong Q3 earnings, eyes growth opportunities

Amylyx Pharmaceuticals had a strong Q3 performance with significant net product revenues and a focus on expanding patient reach. While facing challenges in discontinuations and revenue impact, the company is optimistic about growth opportunities through education and trial results.

Amylyx Pharmaceuticals reports robust earnings, poised for market expansion

Amylyx Pharmaceuticals had a successful year financially, with strong revenue growth and a solid financial position.
The company's focus on expanding market reach, developing innovative biomarkers, and enhancing disease diagnosis underscores their commitment to advancing ALS treatment.
While facing uncertainties with upcoming trial data and regulatory challenges, Amylyx remains optimistic about growth opportunities and R&D advancements.

Amylyx Pharmaceuticals adapts strategy post-PHOENIX trial, eyes regulatory milestones

Amylyx Pharmaceuticals navigated a challenging quarter with a focus on pipeline diversification and strategic planning for multiple neurodegenerative diseases. Despite setbacks in the PHOENIX trial, the company remains resilient and proactive in addressing challenges while seizing opportunities for growth and regulatory progress.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amylyx Pharmaceuticals, Inc. is a commercial-stage biotechnology company, which engages in the provision of therapies for neurodegenerative diseases and amyotrophic lateral sclerosis (ALS). Its commercial product is Relyvrio, also known as Albrioza in Canada. The company was founded by Joshua Cohen and Justin Klee in 2013 and is headquartered in Cambridge, MA.

Amylyx (AMLX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Is Amylyx (AMLX) Stock a Solid Choice Right Now?

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals Announces First Participant Dosed in the Global Phase 3 ORION Study of AMX0035 in Progressive Supranuclear Palsy (PSP).

Amylyx Pharmaceuticals Announces First Participant Dosed in the Global Phase 3 ORION Study of AMX0035 in Progressive Supranuclear Palsy (PSP)

NEW YORK , Dec. 18, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Amylyx Pharmaceuticals, Inc. ("Amylyx" or the "Company") (NASDAQ: AMLX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Amylyx Pharmaceuticals, Inc. - AMLX

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals Announces Publication of Data Showing the Effect of AMX0035 on Plasma Neuroinflammatory Biomarkers in ALS.

Amylyx Pharmaceuticals Announces Publication of Data Showing the Effect of AMX0035 on Plasma Neuroinflammatory Biomarkers in ALS

AbbVie

Alector Inc

Athira Pharma

Coya Therapeutics Inc

GlaxoSmithKline

Anyone who has struggled with a neurodegenerative disease (NDD) or has cared for someone who has one of these illnesses knows how challenging they are to treat and even diagnose. NDDs damage cognitive functions, motor functions, or sometimes both.

These biotechs targeting multiple neurodegenerative diseases

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).

Amylyx Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jazz Pharmaceuticals

Vertex Pharmaceuticals

Investing in biotech stocks is not for risk-averse investors. However, if you're an investor who is serious about generating outsized gains, it's a sector that you can't overlook.

3 Top-Rated Biotech Stocks That Analysts Are Loving Now

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals Appoints Camille L. Bedrosian, MD, as Chief Medical Officer.

Amylyx Pharmaceuticals Appoints Camille L. Bedrosian, MD, as Chief Medical Officer

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--RELYVRIO® and AMX0114 Data to be Presented at 34th International Symposium on ALS/MND.

RELYVRIO® and AMX0114 Data to be Presented at 34th International Symposium on ALS/MND

Amylyx Pharmaceuticals is a biotech company that develops treatments for neurodegenerative diseases, with its product AMX0035 approved by the FDA for ALS therapy. The company's Phase III clinical trials for AMX0035 are expected to yield results in mid-2024, and it plans to seek approval in the EU if the results are satisfactory. AMLX expects to expand the usage of its medication Relyvrio to at least 10,000 patients, leading to significant revenue growth.

Amylyx Pharmaceuticals: A Compelling Buy In The Biotech Sector

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Participate at the 6th Annual Evercore ISI HealthCONx Conference.

Amylyx Pharmaceuticals to Participate at the 6th Annual Evercore ISI HealthCONx Conference

NEW YORK--(BUSINESS WIRE)-- #A--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Amylyx Pharmaceuticals, Inc. (“Amylyx” or the “Company”) (NASDAQ: AMLX) on behalf of Amylyx stockholders. Our investigation concerns whether Amylyx has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. On November 9, 2023, Amylyx issued a press release announcing.

AMYLYX ALERT: Bragar Eagel & Squire, P.C. is Investigating Amylyx Pharmaceuticals, Inc. on Behalf of Amylyx Stockholders and Encourages Investors to Contact the Firm

NEW YORK--(BUSINESS WIRE)---- $AMLX #classactionlawsuit--The law firm of Kirby McInerney LLP is investigating potential claims against Amylyx Pharmaceuticals, Inc. (“Amylyx” or the “Company”) (NASDAQ: AMLX). The investigation concerns whether Amylyx and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices. On November 9, 2023, Amylyx issued a press release announcing its third quarter of 2023 results, including third quarter GAAP earnings-per-share of $0.30.

Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Amylyx Pharmaceuticals, Inc. (AMLX)

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX ) Q3 2023 Earnings Conference Call November 9, 2023 8:00 AM ET Company Participants Lindsey Allen - Head of Investor Relations & Communications Josh Cohen - Co-CEO & Co-Founder Justin Klee - Co-CEO & Co-Founder Margaret Olinger - Chief Commercial Officer James Frates - Chief Financial Officer Conference Call Participants Corinne Jenkins - Goldman Sachs Geoff Meacham - Bank of America Umer Raffat - Evercore ISI Marc Goodman - Leerink Partners Graig Suvannavejh - Mizuho Partners Ananda Ghosh - H.C. Wainwright & Co. Operator Good morning.

Amylyx Pharmaceuticals, Inc. (AMLX) Q3 2023 Earnings Call Transcript

Amylyx missed Wall Street's expectations on Thursday amid struggles for its amyotrophic lateral sclerosis drug, and AMLX stock crashed.

Amylyx Crashes 26% As New ALS Drug Faces A Barrage Of Troubles

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals Reports Third Quarter 2023 Financial Results.

Amylyx Pharmaceuticals Reports Third Quarter 2023 Financial Results

Amylyx Pharmaceuticals, Inc. (AMLX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Amylyx Pharmaceuticals, Inc. (AMLX) Earnings Expected to Grow: What to Know Ahead of Q3 Release

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 9, 2023.

Amylyx Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 9, 2023

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals announces a presentation at Neuro2023 on the design of ORION, a planned global, Phase 3 clinical trial of AMX0035 in PSP.

Amylyx Pharmaceuticals to Present Clinical Trial Design of ORION, a Phase 3 Global Study of AMX0035 in Progressive Supranuclear Palsy (PSP), at the Neuro2023 PSP and CBD International Research Symposium

BioMarin Pharmaceutical

Exelixis

Amylyx has turned a corner toward profitability. BioMarin's focus on rare diseases is paying off.

3 Under-the-Radar Biotech Stocks to Buy in 2023

Amylyx Pharmaceuticals shares fell Friday after its ALS (amyotrophic lateral sclerosis) drug was denied marketing authorization by European Union regulators for the second time.  The repeat rebuff comes after Amylyx asked in June for a formal re-examination of the original denial adopted by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).

Amylyx Pharmaceuticals's ALS dug rejected again by EU regulators

Amylyx Pharmaceuticals Inc. AMLX, -4.60% shares fell 7.5% premarket on Friday after the company said the European Medicines Agency had confirmed its negative opinion on Albrioza, a treatment for amyotrophic lateral sclerosis. The decision comes after a re-examination of the initial negative opinion issued in June.

Amylyx Pharmaceuticals shares fall after ALS treatment is rejected by European regulator

Amylyx Pharmaceuticals said on Friday the European Union medicines regulator for the second time declined to recommend a marketing authorisation for the company's drug to treat amyotrophic lateral sclerosis (ALS).

EU regulator declines to recommend Amylyx' ALS drug

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals Receives Negative CHMP Opinion on its MAA for AMX0035 for the Treatment of ALS in the European Union Following Re-Examination.

Amylyx Pharmaceuticals Receives Negative CHMP Opinion on its Marketing Authorisation Application for AMX0035 for the Treatment of ALS in the European Union Following Re-Examination Process

Verve Therapeutics

Growth stocks have wilted under an avalanche of macro headwinds in late 2023. This broad sell-off, though, may have created some incredible bargains.

News for Amylyx Pharmaceuticals Stock (AMLX)